Organization
Rahway, NJ
9 abstracts
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer.Org: Mayo Clinic, Rochester, MN, AstraZeneca, Gaithersburg, MD,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial.Org: Fred Hutchinson Cancer Center, University of Washington and Fred Hutchinson Cancer Research Centre, Merck & Co., Inc., Rahway, NJ, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.Org: Fred Hutchinson Cancer Research Center, Seattle, WA, American Society of Clinical Oncology, Alexandria, VA, Friends of Cancer Research, Washington, DC,
Abstract
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.Org: Istanbul Medipol University Medical Faculty, International School of Medicine, Merck & Co., Inc., Rahway, NJ, Maria Sklodowska-Curie National Institute of Oncology,
Abstract
Physician-reported barriers and strategies to using tumor mutational burden (TMB) testing in oncology care: An interview based study.Org: Merck and Co., Inc, Rahway, NJ, Merck & Co., Inc., OPEN Health, Parsippany,
Abstract
Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy.Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, MaaT Pharma, Merck & Co., Inc., Rahway, NJ,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,
Abstract
A META-ANALYSIS OF ANALGESIC EFFICACY OF ROFECOXIB 50 MG FROM 13 CLINICAL STUDIESOrg: Clinical Research Centre, SCIREX Corporation, Austin Health, Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Merck and Co., Inc.,